Drug
Abemaciclib clinical trials
Also written LY2835219 and Verzenio.
- studies test it
- 171
- open now
- 62
- in phase 3
- 18
- first study started
- 2009
Keep track of what changes. Save the abemaciclib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Verzenio
- 47
Studies by the year they started
171 studies that test it; most in 2021 (27)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 3 |
| 2014 | 5 |
| 2015 | 8 |
| 2016 | 11 |
| 2017 | 10 |
| 2018 | 7 |
| 2019 | 18 |
| 2020 | 25 |
| 2021 | 27 |
| 2022 | 10 |
| 2023 | 12 |
| 2024 | 13 |
| 2025 | 12 |
| 2026 | 8 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 6
- Phase 1
- 59
- Phase 2
- 104
- Phase 3
- 18
- Phase 4
- 7
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 57 · Other 114
Eli Lilly and Company (41) · National Cancer Institute (NCI) (8) · Dana-Farber Cancer Institute (8) · Memorial Sloan Kettering Cancer Center (7) · Hoffmann-La Roche (4) · AstraZeneca (3) · University of Washington (3) · OHSU Knight Cancer Institute (3)
Often tested with
Tested in the same studies.
Fulvestrant (18) · Palbociclib (14) · Letrozole (13) · Ribociclib (13) · Atezolizumab (11) · Cobimetinib (8) · Bevacizumab (7) · Olaparib (7)
Studies
Open first, then newest update. How each study uses abemaciclib is read from its arms, and is right about nine times in ten.
Testing it · 171
- A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)RecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT06835972Written as Abemaciclib
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue SarcomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT06498648Written as Abemaciclib
- Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP LossRecruitingPhase 1/2Tango Therapeutics, Inc.NCT06810544Written as abemaciclib
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT02523014Written as Abemaciclib
- Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi SarcomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT04941274Written as Abemaciclib
- Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.RecruitingPhase 2City of Hope Medical CenterNCT04305834Written as Abemaciclib
- Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical NeurofibromasRecruitingPhase 1/2National Cancer Institute (NCI)NCT04750928Written as Abemaciclib
- Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast CancerRecruitingPhase 2University of California, IrvineNCT05524584Written as Abemaciclib
- Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal CancerRecruitingPhase 1National Cancer Institute (NCI)NCT06654037Written as Abemaciclib
- ALPINE: Maintenance Letrozole/AbemaciclibRecruitingPhase 2Dana-Farber Cancer InstituteNCT06366347Written as Abemaciclib
- Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerRecruitingPhase 1/2Stemline Therapeutics, Inc.NCT05386108Written as Abemaciclib
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Abemaciclib
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759Written as Abemaciclib
- A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerRecruitingPhase 1/2Genentech, Inc.NCT07100106Written as Abemaciclib
- SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain MetastasesRecruitingPhase 1/2H. Lee Moffitt Cancer Center and Research InstituteNCT04923542Written as Abemaciclib
- Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast CancerRecruitingPhase 2University of WashingtonNCT06179303Written as Abemaciclib
- A Study of Abemaciclib (LY2835219) in Healthy ParticipantsRecruitingPhase 1Eli Lilly and CompanyNCT07818967Written as Abemaciclib Tablet (Test Formulation)
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingPhase 2American Society of Clinical OncologyNCT02693535Written as Abemaciclib (CLOSED TO ENROLLMENT)
- Imlunestrant/Abemaciclib/Selinexor in Ovarian and EndometrialNot yet recruitingPhase 2Dana-Farber Cancer InstituteNCT07832227Written as Abemaciclib
- A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for LiposarcomasRecruitingPhase 1University of WashingtonNCT06025747Written as Abemaciclib
See all 171 studies that test abemaciclib →
Given in every arm · 42 — abemaciclib is usual care beside what is tested
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)RecruitingPhase 3Eli Lilly and CompanyNCT07174336Written as Abemaciclib
- Study of AVZO-021 in Patients With Advanced Solid TumorsRecruitingPhase 1/2Avenzo Therapeutics, Inc.NCT05867251Written as Abemaciclib
- QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant ChemotherapyNot yet recruitingPhase 2Hebei Medical University Fourth HospitalNCT07782840Written as CDK4/6 inhibitor
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingPhase 1/2Eli Lilly and CompanyNCT05768139Written as Abemaciclib
- Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerRecruitingPhase 1/2Ellipses PharmaNCT05573126Written as Abemaciclib
- RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial CancerRecruitingPhase 2Dana-Farber Cancer InstituteNCT03675893Written as Abemaciclib
- ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast CancerRecruitingPhase 2Abramson Cancer Center at Penn MedicineNCT04523857Written as Abemaciclib
- A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast CancerRecruitingPhase 2University of WashingtonNCT07112053Written as Abemaciclib
- Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced CancerRecruitingPhase 1/2Incyclix BioNCT05735080Written as Abemaciclib
- A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BCRecruitingPhase 1/2Forward Pharmaceuticals Co., Ltd.NCT07002177Written as Abemaciclib 150 MG
- Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular SubtypingNot yet recruitingPhase 2Fudan UniversityNCT06561022Written as Abemaciclib
- Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)RecruitingPhase 3Fudan UniversityNCT05891093Written as Abemaciclib
- A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1/2AstraZenecaNCT06188520Written as Abemaciclib
- A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast CancerCompletedPhase 2Eli Lilly and CompanyNCT02747004Written as Abemaciclib
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid TumorsActive, not recruitingPhase 1Eli Lilly and CompanyNCT05307705Written as Abemaciclib
- Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)Active, not recruitingPhase 3AstraZenecaNCT04964934Written as Abemaciclib
- A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Active, not recruitingPhase 3Hoffmann-La RocheNCT06065748Written as Abemaciclib
- A Study of Abemaciclib in Recurrent GlioblastomaActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT02981940Written as Abemaciclib
- An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Active, not recruitingPhase 3AstraZenecaNCT05952557Written as Abemaciclib
- A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerActive, not recruitingPhase 1Eli Lilly and CompanyNCT04188548Written as Abemaciclib
Showing 20 of 42.
As the comparator · 4 — what is tested is compared with abemaciclib
- BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseRecruitingPhase 3BeOne MedicinesNCT07492641Written as Abemaciclib
- Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast CancerNot yet recruitingNot applicableHenan Cancer HospitalNCT07706933Written as Abemaciclib/Ribociclib
- A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBCRecruitingPhase 2National Taiwan University HospitalNCT05766410Written as Abemaciclib
- Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseaseActive, not recruitingPhase 3PfizerNCT06760637Written as abemaciclib
Codes
What other systems call abemaciclib · ClinicalTrials.gg INT000043
- MeSH (NLM) C000590451abemaciclibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 60UAB198HKABEMACICLIBConfirmed FDA, NLM, Wikidata
- RxNorm 1946825Confirmed FDA, Wikidata
- Wikidata Q23901483abemaciclibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C97660AbemaciclibOne source FDA
- DrugBank DB12001One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000590451 | abemaciclib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 60UAB198HK | ABEMACICLIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1946825 | — | Confirmed FDA, Wikidata |
| Wikidata | Q23901483 | abemaciclib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C97660 | Abemaciclib | One source FDA |
| DrugBank | DB12001 | — | One source Wikidata |
Also registered as abemaciclib mesylate (UNII KKT462Q807).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.